The platelet-to-lymphocyte ratio, superior to the neutrophil-to-lymphocyte ratio, correlates with hepatitis C virus infection  by Meng, Xianchun et al.
International Journal of Infectious Diseases 45 (2016) 72–77The platelet-to-lymphocyte ratio, superior to the neutrophil-to-
lymphocyte ratio, correlates with hepatitis C virus infection
Xianchun Meng a,b,1, Gaohui Wei a,b,1, Qian Chang a,b, Ruoyu Peng a,b, Guang Shi a,b,
Peiguo Zheng a,b, Fucheng He a,b, Wanhai Wang a,b,*, Liang Ming a,b,*
a Clinical Laboratory, First Afﬁliated Hospital of Zhengzhou University, Jianshe Road 1st, Zhengzhou, Henan 450052, China
bKey Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China
A R T I C L E I N F O
Article history:
Received 12 November 2015
Received in revised form 18 February 2016
Accepted 25 February 2016
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark.
Keywords:
Platelet-to-lymphocyte ratio
Neutrophil-to-lymphocyte ratio
Severity
Virological response
HCV
S U M M A R Y
Objectives: The platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) have been
studied widely in cancer diseases. However, their correlation with hepatitis C virus (HCV) infection is
unknown. The aim of this study was to investigate the correlation of PLR and NLR with disease severity in
patients with HCV-related liver disease and the virological response in chronic hepatitis C (CHC)
patients.
Methods: The clinical data of 120 HCV-infected patients and 40 healthy controls were analyzed. The
clinical data of 24 CHC patients who had been followed up regularly were collected for the following time
points: before treatment (week 0) and weeks 4, 48, and 72 during treatment. These data were also
analyzed. All data were collected from the database of the hospital patient electronic medical record
system.
Results: The HCV-related cirrhosis group and HCV-related hepatocellular carcinoma group were found
to have lower PLRs (61  31 and 51  23) than the healthy controls (115  23). The PLR of the HCV cleared
group (154  85) was signiﬁcantly higher than that of the HCV untreated group and HCV uncleared group
(90  28 and 88  40, respectively). Receiver operating characteristics curve analysis for the PLR showed an
area under the curve of 0.772 (95% conﬁdence interval 0.674–0.869, p < 0.000); for NLR, the area under the
curve was 0.612 (95% conﬁdence interval 0.495–0.730, p = 0.063). Furthermore, an increasing PLR in CHC
patients indicated a good virological response, and a stable PLR or a downward trend in PLR could predict no
rapid virological response being achieved by week 4, and even no sustained virological response by week 72.
Conclusions: The PLR is closely related to disease severity in patients with HCV-related liver disease and
to the virological response in CHC patients. Dynamic continuous monitoring of the PLR will contribute to
disease surveillance, with an increasing tendency predicting a good virological response.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Chronic hepatitis C (CHC) is an inﬂammatory liver disease
caused by the hepatitis C virus (HCV), which is a major public
health problem and a leading cause of chronic liver disease. With
its characteristic high degree of chronicity, HCV infection often* Corresponding authors. Tel.: +86 037166913072.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).causes chronic inﬂammatory necrosis of the liver, which leads to
liver cirrhosis and even hepatocellular carcinoma (HCC).1 It is
estimated that there are nearly 185 million people infected with
HCV worldwide, with nearly 350 000 people dying each year from
HCV infection-related liver disease. China is a high hepatitis C
epidemic area with about 30 million infected persons, and is the
country with the maximum number of infected cases in the world.2
With its high degree of chronicity, HCV infection is often
associated with disorders of immune function. Studies have
conﬁrmed that cellular immunity plays an important role in the
development of HCV infection, while a variety of cell factors are
also involved.3–5 Different subgroups of lymphocytes, like the
effector T-cells (Teffs), regulatory T-cells (Tregs), and cytotoxicciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Other indicators, such as proteins in the plasma, single nucleotide
polymorphisms (SNPs) on chromosome 19 (rs12979860 and
rs8099917) near the interleukin 28B (IL28B) region, and systemic
levels of interferon gamma inducible protein 10 (IP-10), have been
studied.7,8 However, there is still no satisfactory index to indicate
the progression of HCV-related liver disease or to monitor the
antiviral response to treatment.
Recently, using advanced imaging technology, Guidotti et al.
conﬁrmed that by adhering to platelets in hepatic blood sinuses,
intrahepatic CD8+ effector T-cells recognize and kill cancer cells,
which can be damaged by the liver ﬁbration.9 Also, studies in liver
cancer patients on the platelet-to-lymphocyte ratio (PLR) and
neutrophil-to-lymphocyte ratio (NLR), which are two important
indicators of systemic inﬂammation and have been shown to be
prognostic parameters in various cancer treatments,10–12 have
conﬁrmed that these ratios are closely related to the progression
and treatment outcomes of liver cancer.13–16 Whether these two
parameters are correlated with HCV infection, HCV-related liver
cirrhosis, and HCC has not yet been established. The association of
these two parameters with hepatitis disease progression and
antiviral treatment outcomes, liver ﬁbration, and cancerization
also needs further research.
The aim of this study was to evaluate the clinical values of the
NLR and PLR in HCV-infected patients in order to gain a better
understanding of the role and signiﬁcance of PLR and NLR in HCV
infection-related liver disease. It was also sought to provide new
indicator parameters for the clinical diagnosis of HCV infection and
for HCV treatment.
2. Materials and methods
This study was reviewed and approved by the Institutional
Review Board of the First Afﬁliated Hospital of Zhengzhou
University. Due to the retrospective nature of the study, the need
for informed consent was waived.
2.1. Patients
Following the application of inclusion and exclusion criteria,
120 HCV-infected patients and 40 healthy control subjects from
the First Afﬁliated Hospital of Zhengzhou University, Zhengzhou,
China were included in the study from January 2013 to June
2015. Twenty-four CHC patients who had undergone regular
follow-up for no less than 72 weeks were also included. The
120 patients were divided into different groups: 93 were assigned
to the chronic HCV-related hepatitis group (HCV-Ht), including
31 in the HCV untreated group (HCV-UT), 41 in the HCV cleared
group (HCV-Cl), and 21 in the HCV uncleared group (HCV-UC);
21 were assigned to the HCV-related cirrhosis group (HCV-Cirr)
and six were assigned to the HCV-related HCC group (HCV-HCC).
Cirrhosis and HCC were diagnosed according to clinic standards by
laboratory parameters and liver histopathology tests.
With regard to the inclusion and exclusion criteria, patients
with hepatitis B virus (HBV), HIV, or any other virus infection,
autoimmune diseases such as systemic lupus erythematosus (SLE),
potential immune-related diseases such as diabetes, leukemia or
any other blood system diseases, or any other organic disease
outside the liver were excluded. Patients receiving treatment with
whole blood or any other component blood product transfusions
were also excluded. In the HCV-Cl group, the patients’ viral loads
had been undetectable for at least 24 weeks. Patients in the HCV
treated group were all receiving standard peg-interferon plus
ribavirin antiviral therapy, and no serious adverse effects (anemia,
neutropenia, thrombocytopenia, etc.) were caused by either
interferon or ribavirin. Additionally, healthy controls were subjectswithout a history of any other infectious diseases or drug usage for
the last 6 months. The inclusion and exclusion criteria were based
on the clinical guidelines for HCV infection.17,18
2.2. Data collection
The following data were collected for all healthy control
subjects and patients: age, sex, viral load (VL), alanine amino-
transferase (ALT), aspartate aminotransferase (AST), white blood
cell count (WBC), platelet count (PLT), lymphocyte count,
neutrophil count, and other related clinical indicators. For further
analysis of the correlation of PLR and NLR with antiviral treatment
outcomes, the clinical data of 24 CHC patients who had been
followed up regularly were collected for the following time points:
before treatment (week 0) and weeks 4, 48, and 72 during
treatment.
2.3. Laboratory methods
All specimens were tested within 2 h of collection. Those that
could not be tested immediately were stored at 20 8C for a short
time (no more than 3 days). The HCV-RNA load was tested by
ﬂuorescence quantitative PCR method using the Cobas AmpliPrep/
Cobas Taqman HCV Test and related reagents (Roche, Switzerland).
A Cobas AmpliPrep device was used for fully automated sample
preparation, and a Cobas Taqman analyzer was used for automatic
ampliﬁcation and detection of HCV-RNA. ALT and AST were
detected by enzymatic method using a Cobas E702 automatic
biochemical analyzer and related reagents (Roche), strictly in
accordance with the instructions. The WBC, PLT, lymphocyte, and
neutrophil counts were obtained based on the Coulter principle,
using a Coulter LH 755 automated blood analyzer and related
reagents (Beckman, USA), strictly in accordance with the instruc-
tions. The PLR and NLR were calculated as follows: PLR = platelet
count/lymphocyte count;19 NLR = neutrophil count/lymphocyte
count.20
2.4. Statistical analysis
The statistical analysis was performed using IBM SPSS Statistics
version 21.0 software (IBM Corp., Armonk, NY, USA). Summary
statistics of the study population were expressed as the mean
 standard deviation (mean  SD) or median value with the
interquartile range (IQR), as appropriate. The Kolmogorov–Smirnov
test was performed to evaluate variable distribution. Comparisons of
demographic and clinical parameters of the two groups were
performed using the Chi-square test, Student t-test (independent
samples t-test), or Mann–Whitney U-test, as appropriate; the
Kruskal–Wallis test was used for the comparison of more than two
groups. A receiver operating characteristic (ROC) curve was used for
the evaluation of predictors and to determine their sensitivities and
speciﬁcities. The Friedman test was used to compare the PLR and NLR
of the different virological responders during antiviral treatment. All
p-values of less than 0.05 based on a two-tailed test were considered
statistically signiﬁcant.
3. Results
3.1. General characteristics
A total of 120 HCV-infected patients and 40 healthy controls
were included retrospectively in the present study. The character-
istics of the participants in the two groups are summarized in
Table 1. There was no signiﬁcant difference in mean age or sex ratio
between the patients and controls, while ALT and AST were
considerably higher in patients than in controls (ALT 52  55 vs.
Table 1
Demographic and clinical data for the different patient groups and healthy controlsa
HCV (groups)b HCV (total) Healthy
controls
p-Valuec
HCV-UT HCV-UC HCV-Cl HCV-Cirr HCV-HCC
n 31 21 41 21 6 120 40 NA
Sex, M/F 13/18 9/12 22/19 6/15 2/4 52/68 20/20 0.779
Age, years 42.4  14.1 50.7  9.2 42.2  11.8 53.8  7.4 59.0  7.1 46.6  12.4 45.6  12.9 0.667
ALT, g/l 63  65 90  77 24  26 58  28 29  11 52  55 17  7 0.000
AST, g/l 47  40 65  39 26  19 74  53 51  16 48  40 18  3 0.000
VL, IU/ml 3.89E+06
(6.55E+05,
8.18E+06)
1.01E+06
(2.35E+05,
3.79E+06)
- 9.45E+05
(1.64E+05,
2.09E+06)
1.08E+07
(3.19E+06,
1.74E+07)
2.26E+06
(4.32E+06,
6.73E+06)
- NA
WBC, 109/l 5.0  1.0 4.4  1.4 3.1  1.1 3.0  1.1 5.3  1.3 3.9  1.5 6.4  1.1 0.000
PLT, 109/l 176  55 154  65 154  57 62  41 85  57 140  68 242  41 0.000
Lymphocytes, 109/l 2.0  0.5 1.9  0.6 1.2  0.5 1.1  0.5 1.7  0.6 1.5  0.6 2.2  0.4 0.000
Neutrophils, 109/l 2.4  0.9 2.6  1.1 1.6  0.7 1.5  0.6 2.7  1.0 1.9  0.9 3.7  1.0 0.000
PLR 90  28 88  40 154  85 61  31 51  23 105  67 115  23 0.326
NLR 1.33  0.67 1.19  0.69 1.52  0.79 1.71  1.43 1.92  1.12 1.47  0.92 1.79  0.63 0.042
ALT, alanine aminotransferase; AST, aspartate aminotransferase; F, female; HCV, hepatitis C virus; M, male; NA, not applicable; NLR, neutrophil-to-lymphocyte ratio; PLR,
platelet-to-lymphocyte ratio; PLT, platelets; SD, standard deviation; VL, viral load; WBC, white blood cell count.
a Data are expressed as the mean  SD, and for VL as the median (lower quartile, upper quartile).
b HCV-UT, HCV untreated group; HCV-UC, HCV uncleared group; HCV-Cl, HCV cleared group; HCV-Cirr, HCV-related cirrhosis group; HCV-HCC, HCV-related hepatocellular
carcinoma group. HCV (groups) represent HCV-infected patients of different groups; HCV (total) represents all HCV-infected patients.
c p-Value for the comparison of HCV (total) and healthy control data.
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HCV-infected patients in total (HCV (total)) had signiﬁcantly lower
WBC, PLT, lymphocyte, and neutrophil counts than healthy controls
(WBC 3.9  1.5 vs. 6.4  1.1, p < 0.001; PLT 140  68 vs. 242  41,
p < 0.001; lymphocytes 1.5  0.6 vs. 2.2  0.4, p < 0.001; neutrophils
1.9  0.9 vs. 3.7  1.0, p < 0.001). The characteristics of the patients
in the different HCV-related disease groups are also shown in Table 1.
3.2. Comparison of PLR and NLR of patients with HCV infection at
different disease stages
The association of PLR and NLR with the disease stage in HCV
infection was investigated. As shown in Figure 1, it was found that
the HCV-Cirr and HCV-HCC groups had lower PLR levels
(61  31 and 51  23, respectively) in comparison with the HCV-
Ht and healthy control groups (90  28 and 115  23, respectively);
the differences were statistically signiﬁcant (p < 0.001). For NLR,
there was no changing trend in HCV infection. To summarize, PLR
showed a decreasing trend along with HCV infection-related liver
diseases.Figure 1. Comparison of PLR and NLR in HCV-Ht, HCV-Cirr, and HCV-HCC patients and he
ratio; NLR, neutrophil-to-lymphocyte ratio; HCV-Ht, HCV-related hepatitis group; HCV-Cirr
HC, healthy controls).3.3. Correlation of PLR and NLR with antiviral treatment outcomes in
CHC patients
The correlation of PLR and NLR with hepatitis virus clearance in
CHC patients was then evaluated. As shown in Figure 2, the PLR of
the HCV-Cl group was signiﬁcantly higher than that of the HCV-UT
and HCV-UC groups (154  85 vs. 90  28, p < 0.001; 154  85 vs.
88  40, p = 0.001, respectively). However, the PLRs of the HCV-UT
and HCV-UC groups showed no difference (p = 0.589). For NLR, no
statistically signiﬁcant change was found among the different groups
HCV-UT, HCV-UC, and HCV-Cl.
ROC analysis for the prediction of virus clearance was
conducted next. The ROC curve analysis for PLR showed an area
under the curve (AUC) of 0.772 (95% conﬁdence interval (CI) 0.674–
0.869, p < 0.000), with a speciﬁcity of 92.3% and a sensitivity of
53.7%; for NLR, the AUC was 0.612 (95% CI 0.495–0.730, p = 0.063),
with a speciﬁcity of 76.9% and a sensitivity of 48.8% (Figure 3).
Taken together, PLR and NLR, especially PLR, showed good
indicating function for HCV clearance: a stable lower PLR could
imply an undesirable virological response.althy controls; the data are expressed as the mean  SD (PLR, platelet-to-lymphocyte
, HCV-related cirrhosis group; HCV-HCC, HCV-related hepatocellular carcinoma group;
Figure 2. Comparison of PLR and NLR in CHC patients: HCV-UT, HCV-UC, and HCV-Cl patients, and healthy controls; the data are expressed as the mean  SD (PLR, platelet-to-
lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; CHC, chronic hepatitis C; HCV-UT, HCV untreated group; HCV-UC, HCV uncleared group; HCV-Cl, HCV cleared group).
Figure 3. ROC curves grouped by PLR and NLR. The ROC for PLR is represented by the
short dashed line (AUC = 77.2%, sensitivity 53.7%, speciﬁcity 92.3%) and the ROC for
NLR is represented by the dotted line (AUC = 61.2%, sensitivity 48.8%, speciﬁcity
76.9%) (ROC, receiver operating characteristic; PLR, platelet-to-lymphocyte ratio;
NLR, neutrophil-to-lymphocyte ratio; AUC, area under the curve).
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patients treated with peg-interferon and ribavirin
Based on the above results, 24 regularly followed CHC patients
were reviewed using clinical data obtained before treatment (week
0) and at weeks 4, 48, and 72 during treatment with peg-interferon
and ribavirin. Six patients achieving both a rapid virological
response and a sustained virological response (RVR&SVR),
12 patients achieving a sustained virological response only
(SVR), and six patients not achieving a sustained virological
response (non-SVR) were included. Comparing the PLRs of patients
with the different virological responses, it was found that the PLR
of the RVR&SVR group patients increased noticeably over time
(Figure 4A). For patients in the SVR group, the PLR dropped slightly
at week 4 and then increased gradually over time (Figure 4B).
Conversely, for non-SVR patients, PLR did not rise and sometimes
even dropped over time (Figure 4C). Of note, the NLR of patients
with the different virological responses did not show the same
tendency as the PLR over the treatment course (Figure 4D–F).
Taken together, an increasing PLR in CHC patients was found to
indicate a good virological response; a stable PLR or a downwardtrend in the PLR could predict no RVR achievement by week 4 and
even no SVR by week 72.
4. Discussion
The PLR and NLR, known as systemic inﬂammatory biomarkers,
are immune response-related indicators. Preoperative PLR and NLR
have been considered to be related to the prognosis of aggressive
tumors in various cancers. Many studies have conﬁrmed that one
or both of these is related to the progression and prognosis of
cardiovascular diseases, sudden deafness, vestibular neuritis, and
thrombosis-related diseases.21–23 Meanwhile, the present authors
have noted that chronic infectious diseases, including different
types of viral hepatitis, are characterized by a persistent chronic
inﬂammatory response, and the existing research has also
conﬁrmed that the PLR and NLR are associated with the
progression and prognosis of viral hepatitis-related HCC.13,14 As
the carrier medium role of platelets for immune effector cells is
being clariﬁed,9 the PLR, calculated as the PLT/lymphocyte count
and showing the variation in both platelets and lymphocytes, and
the NLR, calculated as the neutrophil count/lymphocyte count and
showing the variation in both neutrophils and lymphocytes,
comprehensively indicate an immune status change during the
disease period. To date, no studies on the PLR and NLR in HCV
infection-related diseases have been reported.
In the present study, by retrospective analysis of HCV-infected
patients with different stages of liver disease and CHC patients
with different virological responses to treatment with peg-
interferon and ribavirin, it was found that the PLR is closely
related to the stage of HCV infection-related liver disease and the
virological response of CHC patients. Compared with healthy
controls, the PLR of HCV-related cirrhosis and HCC patients were
signiﬁcantly reduced (p < 0.001), while that of CHC patients was
not (p = 0.061). However, there was no signiﬁcant difference
between the PLR of HCV-related cirrhosis patients and that of HCV-
related HCC patients (p = 0.609). Thus, a low PLR could predict an
undesirable progression of HCV infection-related liver disease.
Among the CHC patients, it was found that the PLRs of untreated
patients and those who failed to reach the ideal virology clearance
were reduced, and the PLR of patients with virus clearance was
signiﬁcantly increased. ROC curve analysis also conﬁrmed that PLR
was a good indicator of virus removal. Therefore, PLR is closely
associated with HCV clearance. In contrast, the NLR for HCV-
related liver disease stages and virus clearance in CHC patients did
not show the same tendency, since there was not much signiﬁcant
change in the progression of HCV infection-related liver diseases.
Figure 4. Correlation of PLR and NLR with different virological responses in CHC patients treated with peg-interferon and ribavirin: RVR&SVR, patients achieving both a rapid
virological response and a sustained virological response; SVR, patients achieving a sustained virological response only; non-SVR, patients not achieving a sustained
virological response. (A)–(C) PLRs of patients with different virological responses are shown. (D)–(F) NLRs of patients with different virological responses are shown. Every
round black dot represents a single PLR or NLR value at the corresponding time. The p-values for the comparisons of the levels of PLR or NLR at different weeks during antiviral
treatment were calculated with the Friedman test, a non-parametric repeated measures analysis of variance (ANOVA) (PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-
lymphocyte ratio; CHC, chronic hepatitis C).
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neutrophil counts are all vulnerable to infection and to a variety of
other clinical diseases, and are inclined to great ﬂuctuations,24
patients were assigned to groups strictly according to the inclusion
and exclusion criteria and, furthermore, the clinical data of
24 regularly followed CHC patients were reviewed. The PLRs of
patients who failed to attain a SVR did not vary much, or were evenslightly reduced over the course of treatment. The PLRs of patients
who achieved SVR but not RVR showed a slightly reduced PLR
during the early stage of antiviral treatment (week 4), and then an
obvious increase in PLR to a higher level. The PLRs of patients
achieving both RVR and SVR increased as soon as antiviral
treatment was started and then increased gradually to a higher
level. The apparent individual differences in the PLRs of patients
X. Meng et al. / International Journal of Infectious Diseases 45 (2016) 72–77 77before treatment (week 0) should be noted; the virological
response outcome was closely related to the variation tendency
of the PLR but not to a single PLR value at a certain time point.
Therefore, dynamic continuous monitoring of the patient’s PLR
would be of beneﬁt for the surveillance of disease progression and
prognosis.
The present study appears to be the ﬁrst to show that PLR is
related to the progression of HCV infection-related disease and
the virological response outcome in CHC patients treated with
peg-interferon and ribavirin. The correlation was conﬁrmed by
statistical analysis. However, there are a number of limitations
to this study that should be emphasized. First, the study
retrospectively analyzed a relatively small number of patients
and controls. Accordingly, cause-and-effect relationships can-
not be concluded; prospective longitudinal studies are required
to elucidate any relationships. With a small sample size,
caution must be taken, as the ﬁndings might not be transfer-
able to other populations. Secondly, the evaluation of possible
confounding factors, such as the occurrence of idiopathic
thrombocytopenic purpura (ITP), diabetes mellitus, etc., was
incomplete, and this needs to be taken into account. Future
studies could evaluate whether PLR changes the same way as in
HCV infection only. Moreover, this study was limited to those
patients who attended the First Afﬁliated Hospital of Zhengz-
hou University. As a result, the ﬁndings might not be directly
applicable to subjects from other ethnic groups. Ultimately, the
patients being investigated were mainly infected with HCV
genotype 1b, and the genotype of IL-28 was not taken into
account. Further studies are needed to determine the latent
correlations and mechanisms.
In summary, the current evidence showed that PLR, but not
NLR, is closely related with HCV infection-related disease
progression and the virological response outcome in CHC patients
treated with peg-interferon and ribavirin. Regular follow-up
monitoring of the PLR will contribute to disease surveillance,
since an increasing tendency in PLR predicts a good virological
response outcome. Further studies are needed to determine the
exact mechanisms through which the patient’s PLR changes with
disease progression and antiviral treatment.
In conclusion, the PLR, better than the NLR, correlates tightly
with HCV infection-related disease progression and the virological
response outcome in CHC patients. Dynamic continuous monitor-
ing of the PLR, rather than a single high or low PLR value at a certain
time point, will contribute to disease surveillance, with an
increasing tendency predicting a good virological response. Taken
together, the platelet-to-lymphocyte ratio (PLR), superior to
neutrophil-to-lymphocyte ratio (NLR), correlates with the disease
severity of HCV infection.
Acknowledgements
The authors thank the Medical Records Room and the
Department of Clinical Laboratory of the First Afﬁliated Hospital
of Zhengzhou University for kindly providing facilities.Conﬂict of interest: This study was supported by grants from the
National Natural Science Foundation of China (No.U1204811). The
authors report no conﬂicts of interest.
References
1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV
infection. Nat Rev Gastroenterol Hepatol 2013;10:553–62.
2. Sharma S, Carballo M, Feld JJ, Janssen HL. Immigration and viral hepatitis. J
Hepatol 2015;63(2):515–22.
3. Vasallo C, Gastaminza P. Cellular stress responses in hepatitis C virus infection:
mastering a two-edged sword. Virus Res 2015;209:100–17.
4. Saha B, Szabo G. Innate immune cell networking in hepatitis C virus infection. J
Leukoc Biol 2014;96:757–66.
5. Larrubia JR, Moreno-Cubero E, Lokhande MU, Garcia-Garzon S, Lazaro A, Miquel
J, et al. Adaptive immune response during hepatitis C virus infection. World J
Gastroenterol 2014;20:3418–30.
6. Claassen MA, Janssen HL, Boonstra A. Role of T cell immunity in hepatitis C virus
infections. Curr Opin Virol 2013;3:461–7.
7. Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, et al.
Discovery of novel biomarker candidates for liver ﬁbrosis in hepatitis C
patients: a preliminary study. PLoS One 2012;7:e39603.
8. Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, et al. The comple-
ment component C3a fragment is a potential biomarker for hepatitis C virus-
related hepatocellular carcinoma. J Gastroenterol 2010;45:459–67.
9. Guidotti LG, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L, et al.
Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell
2015;161:486–500.
10. Sidaway P. Prostate cancer: platelet-to-lymphocyte ratio predicts prostate
cancer prognosis. Nat Rev Urol 2015;12(5):238.
11. Kim EY, Lee JW, Yoo HM, Park CH, Song KY. The platelet-to-lymphocyte ratio
versus neutrophil-to-lymphocyte ratio: which is better as a prognostic factor in
gastric cancer? Ann Surg Oncol 2015.
12. Choi WJ, Cleghorn MC, Jiang H, Jackson TD, Okrainec A, Quereshy FA. Preopera-
tive neutrophil-to-lymphocyte ratio is a better prognostic serum biomarker
than platelet-to-lymphocyte ratio in patients undergoing resection for non-
metastatic colorectal cancer. Ann Surg Oncol 2015;22(13):4363–70.
13. Li X, Chen ZH, Xing YF, Wang TT, Wu DH, Wen JY, et al. Platelet-to-lymphocyte
ratio acts as a prognostic factor for patients with advanced hepatocellular
carcinoma. Tumour Biol 2015;36:2263–9.
14. Peng W, Li C, Zhu WJ, Wen TF, Yan LN, Li B, et al. Prognostic value of the platelet
to lymphocyte ratio change in liver cancer. J Surg Res 2015;194:464–70.
15. Xue TC, Jia QA, Ge NL, Zhang BH, Wang YH, Ren ZG, et al. The platelet-to-
lymphocyte ratio predicts poor survival in patients with huge hepatocellular
carcinoma that received transarterial chemoembolization. Tumour Biol
2015;36(8):6045–51.
16. Lai Q, Castro SE, Rico JJ, Pinheiro RS, Lerut J. Neutrophil and platelet-to-
lymphocyte ratio as new predictors of dropout and recurrence after liver
transplantation for hepatocellular cancer. Transpl Int 2014;27:32–41.
17. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing,
and treating adults infected with hepatitis C virus. Hepatology 2015;62:932–54.
18. World Health Organization. Guidelines for the screening, care and treatment of
persons with hepatitis C infection. Geneva: WHO; 2014.
19. Smith RA, Bosonnet L, Ghaneh P, Sutton R, Evans J, Healey P, et al. The platelet-
lymphocyte ratio improves the predictive value of serum CA19-9 levels in
determining patient selection for staging laparoscopy in suspected periampul-
lary cancer. Surgery 2008;143:658–66.
20. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte
ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181–4.
21. Chung JH, Lim J, Jeong JH, Kim KR, Park CW, Lee SH. The signiﬁcance of
neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in vestibular
neuritis. Laryngoscope 2015;125(7):E257–61.
22. Yayla C, Akboga MK, Canpolat U, Akyel A, Yayla KG, Dogan M, et al. Platelet to
lymphocyte ratio can be a predictor of infarct-related artery patency in patients
with ST-segment elevation myocardial infarction. Angiology 2015;66(9):831–6.
23. Yang W, Liu Y. Platelet–lymphocyte ratio is a predictor of venous thromboem-
bolism in cancer patients. Thromb Res 2015;136(2):212–5.
24. Chabot-Richards DS, George TI. White blood cell counts: reference methodolo-
gy. Clin Lab Med 2015;35:11–24.
